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AbstrACt
Objectives To investigate the proportion of potentially 
relevant undisclosed financial ties between clinical 
practice guideline writers and pharmaceutical companies.
Design Cross-sectional study of a stratified random 
sample of Australian guidelines and writers.
setting Guidelines available from Australia’s National 
Health and Medical Research Council guideline database, 
2012–2014, stratified across 10 health priority areas.
Population 402 authors of 33 guidelines, including up to 
four from each area, dependent on availability: arthritis/
musculoskeletal (3); asthma (4); cancer (4); cardiovascular 
(4); diabetes (4); injury (3); kidney/urogenital (4); mental 
health (4); neurological (1); obesity (1). For guideline 
writers with no disclosures, or who disclosed no ties, a 
search of disclosures in the medical literature in the 5 
years prior to guideline publication identified potentially 
relevant ties, undisclosed in guidelines. Guidelines were 
included if they contained recommendations of medicines, 
and writers included if developing or writing guidelines.
Main outcome measures Proportions of guideline writers 
with potentially relevant undisclosed financial ties to 
pharmaceutical companies active in the therapeutic area; 
proportion of guidelines including at least one writer with a 
potentially relevant undisclosed tie.
results 344 of 402 writers (86%; 95% CI 82% to 89%) 
either had no published disclosures (228) or disclosed 
they had no ties (116). Of the 344 with no disclosed ties, 
83 (24%; 95% CI 20% to 29%) had potentially relevant 
undisclosed ties. Of 33 guidelines, 23 (70%; 95% CI 51% 
to 84%) included at least one writer with a potentially 
relevant undisclosed tie. Writers of guidelines developed 
and funded by governments were less likely to have 
undisclosed financial ties (8.1%vs30.6%; risk ratio 0.26; 
95% CI 0.13 to 0.53; p<0.001).
Conclusions Almost one in four guideline writers with no 
disclosed ties may have potentially relevant undisclosed 
ties to pharmaceutical companies. These data confirm the 
need for strategies to ensure greater transparency and 
more independence in relationships between guidelines 
and industry.
IntrODuCtIOn  
There is global concern about the nature 
and extent of financial ties between 
pharmaceutical companies and health 
professionals, including those who develop 
influential clinical practice guidelines.1–3 
In 2009, a landmark Institute of Medicine 
report on conflicts of interest acknowl-
edged the importance of collaboration with 
industry, but warned financial ties to industry 
were widespread and risked jeopardising the 
integrity of medical education, research and 
practice, and called for greater transparency 
and independence.1 A subsequent Institute 
of Medicine report, titled ‘Clinical prac-
tice guidelines we can trust’, recommended 
that groups developing guidelines ‘opti-
mally comprise members without conflict of 
interest.’2 Systematic review evidence suggests 
most guideline writers disclose some form of 
industry affiliation, with estimates between 
56% and 87%.3 There are, however, few data 
on the extent of undisclosed financial ties of 
guideline writers. One study of North Amer-
ican cholesterol and diabetes guidelines esti-
mated 11% of writers had undisclosed ties,4 
another study of American head and neck 
surgery guidelines found 6% had discrep-
ancies between disclosures and an open 
payments database,5 while a Danish study 
strengths and limitations of this study
 ► Our study is the largest to date to examine undis-
closed ties of guideline writers and includes a broad 
sample of guidelines across 10 disease categories.
 ► Our study includes guidelines with different funding 
and development arrangements, enabling compari-
son of guidelines funded and developed by govern-
ment, with other guidelines.
 ► Our study did not investigate the undisclosed ties 
of guideline writers who had disclosed ties in the 
sample of guidelines analysed.
 ► Study results likely underestimate the extent of un-
disclosed financial ties of guideline writers.
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of 14 specialty society guidelines found 52% had undis-
closed ties.6 (For  consistency, the term guideline writer is 
used throughout to refer to those who develop, draft and 
author guidelines.) 
A conflict of interest is defined as “a set of circum-
stances that creates a risk that professional judgement or 
actions regarding a primary interest will be unduly influ-
enced by a secondary interest”.1 A primary interest of a 
guideline writer may be maximising health outcomes, 
and a secondary interest could be personal gain derived 
from a financial relationship with a company active in 
the relevant therapeutic area. Evidence from other areas, 
such as clinical trials, has shown such conflicts of interest 
may introduce bias. A recent systematic review found 
drug trials sponsored by industry more often have effi-
cacy results and conclusions favourable to the sponsor.7 
Similarly, a cross-sectional study of randomised trials 
found those authored by principal investigators with 
ties to pharmaceutical companies were more likely than 
other trials to report favourable results.8 Such evidence 
has provoked debate about the optimum constitution of 
guideline groups, with calls for chairs and a majority of 
writers to be free of financial ties,9 10 as well as recommen-
dations for exclusion of any conflicted writer.2
In Australia, the publicly funded National Health 
and Medical Research Council (NHMRC) is currently 
engaged in improving standards for guideline develop-
ment, including in relation to transparency and manage-
ment of conflicts of interest. An internal analysis of 9 years 
of Australian guidelines made available via the NHMRC 
guideline portal, 2005–2013, found only 12% of guide-
lines published declarations of the conflicts of interest 
of guideline writers.11 As part of work to improve stan-
dards of guidelines which can have direct impacts on how 
clinicians deliver care to their patients, the NHMRC is 
developing new ‘guidelines for guidelines’, and a draft 
released for public comment in 2017 included the recom-
mendation: “Organisations planning guidelines should 
aim to appoint a guideline development group whose 
members have no financial or other links with relevant 
industry groups”.12 In order to inform ongoing efforts to 
improve guideline quality in Australia and internation-
ally, our objective was to investigate the extent of undis-
closed financial ties to industry, for a broad cross-section 
of guideline writers from different categories of guide-
line developer, sampled from a comprehensive national 
guideline database, across a wide spectrum of diseases.
MethODs
We conducted a cross-sectional study of a stratified 
random sample of Australian clinical practice guidelines 
and followed the STROBE checklist for reporting obser-
vational studies (see online supplementary file 1).13
sampling guidelines
We identified a stratified random sample of clinical 
practice guidelines from within the NHMRC guidelines 
database, across nine government-designated health 
priority areas (https:// nhmrc. gov. au/ about- us/ publi-
cations/ nhmrc- corporate- plan- 2017- 2018) plus kidney/
urogenital, published in the years 2012–2014. The 
NHMRC database comprised guidelines made available 
on the publicly accessible NHMRC guidelines portal, 
which aimed to include all Australian guidelines, 
defined broadly as published articles making clinical 
recommendations. While the NHMRC portal at that 
time included all Australian guidelines, it also provided 
users of the portal with information on quality indica-
tors for these guidelines, such as whether the guideline 
was based on a systematic review of evidence, whether 
the authors provided conflict of interest disclosures 
and whether or not the guideline had been approved 
by NHMRC. From 2015, the NHMRC portal restricted 
the inclusion of guidelines to only include guidelines 
which met certain quality standards, so to achieve a 
representative sample from the comprehensive collec-
tion of widely used Australian guidelines, we analysed 
guidelines available on the portal in the 3 years leading 
up to the change.
In 2017, NHMRC staff (HJ) identified all guidelines 
in the database, published in the years 2012–2014, and 
used previous coding by NHMRC to exclude articles 
not relevant to the 10 health areas of interest, those 
not considered guidelines, including those coded as 
Evidence Reviews, Posters/Flowcharts, Standards and 
Summary guidelines. Following the initial screen, each 
guideline was randomly ordered using Microsoft Excel 
within each of the 10 health areas. Two authors (LB, 
RM) then assessed each guideline in the order they had 
been ranked, against explicit inclusion criteria, and iden-
tified guideline writers to be included in the analysis. 
Guidelines were included if they were associated with a 
professional organisation or entity and made mention 
of medicines in recommendations. They were excluded 
if they were a journal article unconnected from an 
external organisation, or if no author names or full text 
was available. Guideline writers listed in the guideline 
were included for analysis if they were explicitly engaged 
in developing, preparing or writing the guideline, and 
excluded if they were external consultants, members 
of oversight committees or staff from a drug company, 
NHMRC or administrative staff. Any discrepancies were 
resolved by discussion.
The primary unit of analysis was the guideline writer. 
Based on assumptions that 10% of guideline writers 
might have an undisclosed relevant financial tie, and that 
guidelines would have 4–20 writers each, we estimated a 
need for a minimum sample of 12 guidelines—aiming for 
approximately 140 writers—to produce a CI of a width 
of 10% around our estimate of the proportion of writers 
with undisclosed ties. In addition, to obtain as broad a 
cross-section as possible, we aimed to analyse up to four 
guidelines per health priority/disease area, depending 
on guideline availability.
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Guideline and author information
One investigator (either AL or RM) extracted all rele-
vant information from each included guideline into 
the REDCap electronic data capture tools hosted at 
the University of Sydney.14 The extracted information 
included the names of all included writers, classified in 
one of three ways: disclosure of ties; disclosure of no ties; 
no disclosure present. Disclosures were those included in 
the guideline document or associated publicly available 
documents. Information on whether the guideline had 
a statement on conflicts of interest, and the developer/s 
and funder/s was also extracted.
Identification of potentially relevant undisclosed financial ties
For any guideline writer with no declaration present, or 
who declared no conflicts of interests, one investigator 
(AL or RM) conducted a search of the writer’s publica-
tions in the 5 years before the year of guideline publica-
tion. The period of 5 years was chosen for the following 
reasons: many guidelines are estimated to be at least 
2 years in development before the year of publication; 
disclosures are directly relevant at the start of the process 
of guideline development; WHO guidance suggests a 
period of 4 years prior to publication is relevant when 
disclosing financial ties15; many disclosure policies have 
a recall period of 3 to 5 years.16 Publications were also 
searched in the 3 years following guideline publication, 
as some organisations, including the Institute of Medi-
cine, recommend guideline writers be free of conflicts for 
periods of time after guideline publication.17
The Scopus database was used to search for publications 
of guideline writers using their names and affiliations. 
Full texts were obtained. Searches were conducted from 
the earliest date and as per Forsyth et al18 were stopped 
once a potentially relevant financial tie was identified. A 
potentially relevant tie was defined as a financial tie to 
a pharmaceutical company actively marketing or in late 
stages of bringing a medicine to market in the therapeutic 
area relevant to the guideline, at the time of the guideline 
publication, determined through searches of company 
websites and relevant product information material. Cate-
gorisation of ties was developed based on criteria set by 
the International Committee of Medical Journal Editors, 
ICMJE, and based on adaptations of ICMJE criteria 
used in a previous study,18 including grants (funding 
for research study), personal fees (consulting, advisory, 
speakers, honoraria, travel), patents/copyrights/royal-
ties and miscellaneous. Once a potentially relevant tie was 
identified by one author (AL or RM), a second author 
(RM or LB) double checked the full text of the disclosure 
and verified the tie as a potentially relevant tie, and any 
discrepancies were resolved by discussion. Searches were 
conducted between August and December 2017.
Outcome measures and statistical analysis
The primary outcome measures were specified as the 
proportion of guideline writers with potentially rele-
vant undisclosed ties, and the proportion of guidelines 
in the sample which included at least one writer with an 
undisclosed tie. Secondary outcome measures were the 
proportion of writers with disclosed ties, the proportion 
of guidelines which have any statement about conflicts 
of interest, and the proportion of guidelines developed 
and funded by governments (state, federal or territories). 
We report data proportions using descriptive statistics 
and including 95% CIs. We examined the association 
between having statements and the proportion of poten-
tially relevant undisclosed ties of writers, and the associa-
tion between a guideline being developed and funded by 
government/s and the proportion of potentially relevant 
undisclosed ties of writers. Potential associations were 
tested using the χ2 test. CIs were not adjusted for clus-
tering of writers within multiple guidelines or for clus-
tering of guidelines within disease area.
ethics
As all publications analysed for this study were on the 
public record, the chair of Bond University’s Human 
Research Ethics committee asserted that the study did not 
require ethics review if no individuals were identified or 
described.
Patient and public involvement
No patients or members of the public were involved in 
this study.
results
Characteristics of guidelines
There was a total of 347 guidelines in the NHMRC data-
base, published 2012–2014 (figure 1). The initial screen 
excluded 11 items not considered guidelines, coded by 
NHMRC as Evidence Reviews, Posters/Flowcharts, Stan-
dards and Summary guidelines, 62 because they did not 
contain names of those who had developed the guideline 
and 129 published outside the 10 health areas in this study. 
The remaining 145 guidelines were assigned a random 
number to establish a random order for assessment of 
the guidelines within each of the 10 health areas. We 
continued to assess guidelines within each area in random 
order until we had included four for each health area or 
had completed assessing all the available guidelines in a 
given health area. In total, LB and RM assessed 82 guide-
lines. Forty-nine of those guidelines were excluded after 
assessment because they were a publication only with no 
affiliation to any external organisation (n=22), had no 
recommendations about medications (n=25), or the full 
text or author list of the guideline was not publicly avail-
able (n=2). Sixty-three were not assessed.
We included 33 guidelines in our final sample: arthritis/
musculoskeletal (n=3); asthma (n=4); cancer (n=4); 
cardiovascular (n=4); diabetes (n=4); injury (n=4); mental 
health (n=4); neurological (n=1); obesity (n=1); kidney/
urogenital (n=4) (online supplementary file 2). The 33 
guidelines involved a total of 402 guideline writers, with 
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individual guidelines having between 2 and 35 writers 
included for analysis.
Prevalence of undisclosed ties
Among all 402 guideline writers, 58 disclosed ties (14%; 
95% CI 11% to 18%) (table 1). Among the 402 writers, 
344 had no disclosed ties (86%; 95% CI 82% to 89%), 
including 228 writers where no disclosures appeared 
and 116 writers with statements that they had no ties. Of 
the 344 writers with no disclosed ties, 83 had at least one 
potentially relevant undisclosed tie (24%; 95% CI 20% 
to 29%), discovered in the published literature in the 
same year as the guideline was published or the previous 
5 years. Of those undisclosed ties, the first category of 
tie listed in the relevant disclosure was pharmaceutical 
company grant (64%) or personal fees (36%). If the time 
frame was extended to 3 years after the guideline, the 
proportion of potentially relevant undisclosed ties rose 
from 24% to 28% (95% CI 23% to 33%).
Of 33 guidelines, 23 included at least one writer with 
a potentially relevant undisclosed tie (70%; 95% CI 51% 
to 84%) (figure 2). Of those 23 guidelines, 14 guidelines 
had 20% or more writers who disclosed no ties, but had 
potentially relevant undisclosed ties. Figure 2 also reveals 
the proportion of undisclosed ties of guideline writers 
who disclosed no ties, per guideline, grouped by disease 
category.
Guideline characteristics and undisclosed ties
Guidelines which included any statement about conflicts 
of interest were not significantly different from those 
without statements: 59 of 223 writers (27%) had poten-
tially relevant undisclosed ties, compared with 24 of 
121 writers (20%) (risk ratio 1.33; 95% CI 0.88 to 2.03; 
p=0.170) (table 2). Guidelines both developed and 
funded by governments, as opposed to non-government 
groups (including professional bodies, foundations or 
pharmaceutical companies), were significantly less likely 
to have authors with potentially relevant undisclosed ties: 
8 of 99 writers (8%) compared with 75 of 245 writers 
(31%) (risk ratio 0.26; 95% CI 0.13 to 0.53; p<0.001).
Figure 1 Flowchart for sample. NHMRC, National Health and Medical Research Council. 
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DIsCussIOn
In this broad cross-sectional sample of Australian clin-
ical practice guidelines, 14% of guideline writers had 
published disclosures of conflicts of interest. Among 
those who either had no disclosures or disclosed they 
had no conflicts, 24%—almost one in four—had at 
least one potentially relevant undisclosed financial 
tie to a pharmaceutical company active in the thera-
peutic area. More than two-thirds, or 70%, of the 33 
guidelines in this sample had at least one writer with 
an undisclosed tie. Undisclosed financial ties of guide-
line writers appeared to be more common in some 
therapeutic areas such as diabetes and cardiovascular 
disease, compared with other areas such as injury and 
mental health. Guideline writers working on guidelines 
developed and funded by government were much less 
likely to have undisclosed financial ties: 8% compared 
with 31%.
Table 1 Characteristics of guideline writers from a stratified random sample of guidelines, 2012–2014 (n=33)
Therapeutic 
area
Clinical practice 
guideline (ID 
number)
Total number of 
writers
Number with 
disclosed ties
Number with no 
disclosed ties
COI statement 
available
Developed 
and funded by 
government
Arthritis 1 15 0 15 Yes No
2 26 2 24 Yes No
3 6 0 6 No Yes
Asthma 4 14 0 14 No Yes
5 7 0 7 No No
6 6 0 6 No No
7 6 4 2 Yes No
Cancer 8 27 4 23 Yes No
9 6 1 5 Yes No
10 14 0 14 Yes Yes
11 31 0 31 No Yes
Cardiovascular 12 11 4 7 Yes No
13 4 0 4 No No
14 8 1 7 Yes No
15 34 0 34 Yes No
Diabetes 16 4 0 4 No No
17 14 0 14 No No
18 5 5 0 Yes No
19 13 0 13 Yes No
Injury 20 18 0 18 No Yes
21 2 0 2 No Yes
22 35 4 31 Yes No
23 9 0 9 Yes Yes
Kidney 24 7 1 6 Yes No
25 9 2 7 Yes No
26 6 2 4 Yes No
27 13 0 13 No No
Mental health 28 10 10 0 Yes Yes
29 11 11 0 Yes Yes
30 9 0 9 Yes No
31 8 0 8 Yes No
Neurological 32 2 0 2 No No
Obesity 33 12 7 5 Yes Yes
Total 402 58 344
COI, conflict of interest.
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There are important limitations to this study. First, the 
results likely underestimate the frequency of undisclosed 
ties for several reasons: there is a general under-reporting 
of ties published in medical journals as many important 
transfers of benefits to professionals, such as hospitality 
or industry-subsidised education, are not routinely 
disclosed; Australia did not at the time have a database 
with information on company payments to individuals; 
and we did not search for any potentially relevant undis-
closed ties of writers who made disclosures of ties in the 
guideline, whether those ties were to pharmaceutical 
companies or other groups. Second, our results may tend 
to a small degree to overestimate the frequency of undis-
closed ties, through what some may see as a broad defi-
nition of potential relevance; for example, categorising 
a co-investigator of a study funded by a pharmaceutical 
company active in the therapeutic area as a potentially 
relevant tie. Third, the sample of guidelines, while broad 
and accessible, comes from 2012 to 2014—the most 
recent years available for this sample from a comprehen-
sive collection—admitting the possibility of change since 
that time. And fourth, we looked only at financial ties, not 
other non-financial conflicts of interest. The strengths 
of the study lie in it being the largest to date in terms 
of guideline writers and undisclosed ties to industry, as 
well as covering a broad cross-section of disease catego-
ries and guideline developers—both government and 
non-government—with previous smaller studies limited 
to specific therapeutic areas,4 5 or guidelines produced 
only by specialty societies.6
Neuman and colleagues investigated the prevalence of 
conflicts of interest among panels producing 14 North 
American guidelines for high cholesterol and diabetes.4 
They reported that among writers who formally declared 
no conflicts, 11% had one or more. Looking at a small 
sample of 49 writers of head and neck surgery guide-
lines, Horn and colleagues found 6% had discrepancies 
between guideline disclosures and information available 
in the Open Payments transparency database.5 Analysing 
Danish specialty society guidelines, and cross-checking 
disclosures against a public register of disclosures, Bind-
sley and colleagues estimated 52% of 254 guideline writers 
had not disclosed ties.6 A possible explanation of why our 
estimate of 24% sits within these finding is that the North 
American studies used narrower timeframes to search for 
undisclosed ties, while the Danish study defined a conflict 
of interest as any affiliation with any drug company.
As others have stated, guideline writer ties to compa-
nies with interest in the guideline’s outcome raise crit-
ical questions about potential bias in processes that may 
have great impacts on the use of healthcare interven-
tions,4 12 disease definitions19 and patient care. Findings 
of potentially relevant undisclosed ties compound the 
problem further and raise the spectre of hidden bias, 
increasing the wariness of guideline users. Contemporary 
community standards now demand total transparency, 
and our findings of undisclosed ties add weight to calls 
for reforms like the Sunshine Act and Open Payments 
system in the USA,20 ‘publicly accessible registries of 
researcher conflicts of interest’,21 and more immediately, 
Figure 2 Proportion of Australian clinical practice guideline writers with undisclosed ties, 2012–2014.
Table 2 Proportion of guidelines writers with undisclosed financial ties by guideline type
Yes No Risk ratio (95% CI) P value
COI statement in 
guideline
59/223 (26.5%) 24/121 (19.8%) 1.33 (0.88 to 2.03) 0.170
Developed, funded by 
government/s
8/99 (8.1%) 75/245 (30.6%) 0.26 (0.13 to 0.53) <0.001
P value refers to χ2 test.
COI, conflict of interest.
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enforcement of current disclosure policies to minimise 
undisclosed ties. In line with repeated recommendations 
for greater independence between health professionals 
and industry,1 2 12 our incidental finding that almost one 
in five of these guidelines had less than 10% of writers 
with any ties to industry shows it is possible to assemble 
guideline panels almost entirely free of financial conflicts 
of interest.
The related reform processes of enhanced transparency 
and greater independence underway in many nations 
creates clear opportunities for research comparing the 
quality of guidelines developed by writers with and without 
links to industry, a research question beyond the scope of 
this study, and where there are currently limited data.22 
Similarly, there is a need for more research investigating 
the impacts of links between industry and the professional 
organisations which auspice guideline development, with 
one recent study suggesting such ties are ‘common and 
infrequently disclosed’.23 Given their potential influence 
over human health, and health system sustainability, such 
vital research on the independence and trustworthiness 
of guidelines will be greatly enhanced by complete trans-
parency around the financial conflicts of interest of those 
developing them.
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